A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder

The efficacy and safety of risperidone long-acting injectable (LAI) for preventing recurrence of mood episodes in patients with bipolar I disorder was evaluated in a randomized, placebo-controlled study. After a 12-week open-label period with risperidone LAI (n=560), patients who did not experience...

Full description

Autores:

Tipo de recurso:

Fecha de publicación:

2012

Institución:

Universidad del Rosario

Repositorio:

Repositorio EdocUR - U. Rosario

Idioma:

eng

OAI Identifier:

oai:repository.urosario.edu.co:10336/26389

Acceso en línea:

https://doi.org/10.1016/j.euroneuro.2012.03.004
https://repository.urosario.edu.co/handle/10336/26389

Palabra clave:

Atypical antipsychotics
Bipolar disorder
Long-acting injectable
Placebo-controlled trial
Recurrence
Risperidone

Rights

License

Abierto (Texto Completo)